Annual CFO
-$10.30 M
+$2.94 M+22.22%
31 December 2023
Summary:
Qualigen Therapeutics annual cash flow from operations is currently -$10.30 million, with the most recent change of +$2.94 million (+22.22%) on 31 December 2023. During the last 3 years, it has risen by +$4.43 million (+30.05%). QLGN annual CFO is now -18083.07% below its all-time high of $57.30 thousand, reached on 31 March 2020.QLGN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$1.80 M
-$325.40 K-22.07%
30 September 2024
Summary:
Qualigen Therapeutics quarterly cash flow from operations is currently -$1.80 million, with the most recent change of -$325.40 thousand (-22.07%) on 30 September 2024. Over the past year, it has increased by +$3.87 million (+68.26%). QLGN quarterly CFO is now -293.60% below its all-time high of $929.70 thousand, reached on 30 September 2023.QLGN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$9.73 M
-$2.73 M-38.99%
30 September 2024
Summary:
Qualigen Therapeutics TTM cash flow from operations is currently -$9.73 million, with the most recent change of -$2.73 million (-38.99%) on 30 September 2024. Over the past year, it has increased by +$574.70 thousand (+5.58%). QLGN TTM CFO is now -5490.36% below its all-time high of $180.50 thousand, reached on 30 September 2019.QLGN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
QLGN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +68.3% | +5.6% |
| 3 y3 years | +30.1% | +38.2% | +34.0% |
| 5 y5 years | - | -555.6% | -5490.4% |
QLGN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +30.1% | -293.6% | +68.3% | -41.6% | +41.1% |
| 5 y | 5 years | <-9999.0% | +30.1% | -293.6% | +73.2% | -5490.4% | +41.1% |
| alltime | all time | <-9999.0% | +30.1% | -293.6% | +73.2% | -5490.4% | +41.1% |
Qualigen Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.80 M(+22.1%) | -$9.73 M(+39.0%) |
| June 2024 | - | -$1.47 M(+88.2%) | -$7.00 M(-17.2%) |
| Mar 2024 | - | -$783.60 K(-86.2%) | -$8.45 M(-18.0%) |
| Dec 2023 | -$10.30 M(-22.2%) | -$5.67 M(-710.0%) | -$10.30 M(+50.0%) |
| Sept 2023 | - | $929.70 K(-131.7%) | -$6.87 M(-37.4%) |
| June 2023 | - | -$2.93 M(+11.2%) | -$10.98 M(-8.5%) |
| Mar 2023 | - | -$2.63 M(+17.7%) | -$12.00 M(-9.4%) |
| Dec 2022 | -$13.25 M | -$2.24 M(-29.7%) | -$13.25 M(-4.9%) |
| Sept 2022 | - | -$3.18 M(-19.4%) | -$13.92 M(+1.1%) |
| June 2022 | - | -$3.95 M(+1.7%) | -$13.77 M(-16.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$3.88 M(+33.2%) | -$16.53 M(+12.2%) |
| Dec 2021 | -$14.73 M(+44.9%) | -$2.91 M(-3.9%) | -$14.73 M(+24.7%) |
| Sept 2021 | - | -$3.03 M(-54.8%) | -$11.82 M(-11.2%) |
| June 2021 | - | -$6.70 M(+222.1%) | -$13.30 M(+51.4%) |
| Mar 2021 | - | -$2.08 M(-53.9%) | -$8.79 M(+31.0%) |
| Dec 2020 | -$10.16 M(<-9900.0%) | - | - |
| Sept 2020 | - | -$4.52 M(+106.2%) | -$6.71 M(+273.7%) |
| June 2020 | - | -$2.19 M(-654.2%) | -$1.79 M(-1094.3%) |
| Mar 2020 | $57.30 K | - | - |
| Sept 2019 | - | $395.10 K(-284.1%) | $180.50 K(-184.1%) |
| June 2019 | - | -$214.60 K | -$214.60 K |
FAQ
- What is Qualigen Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Qualigen Therapeutics?
- What is Qualigen Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Qualigen Therapeutics?
- What is Qualigen Therapeutics quarterly CFO year-on-year change?
- What is Qualigen Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Qualigen Therapeutics?
- What is Qualigen Therapeutics TTM CFO year-on-year change?
What is Qualigen Therapeutics annual cash flow from operations?
The current annual CFO of QLGN is -$10.30 M
What is the all time high annual CFO for Qualigen Therapeutics?
Qualigen Therapeutics all-time high annual cash flow from operations is $57.30 K
What is Qualigen Therapeutics quarterly cash flow from operations?
The current quarterly CFO of QLGN is -$1.80 M
What is the all time high quarterly CFO for Qualigen Therapeutics?
Qualigen Therapeutics all-time high quarterly cash flow from operations is $929.70 K
What is Qualigen Therapeutics quarterly CFO year-on-year change?
Over the past year, QLGN quarterly cash flow from operations has changed by +$3.87 M (+68.26%)
What is Qualigen Therapeutics TTM cash flow from operations?
The current TTM CFO of QLGN is -$9.73 M
What is the all time high TTM CFO for Qualigen Therapeutics?
Qualigen Therapeutics all-time high TTM cash flow from operations is $180.50 K
What is Qualigen Therapeutics TTM CFO year-on-year change?
Over the past year, QLGN TTM cash flow from operations has changed by +$574.70 K (+5.58%)